MAIA Biotechnology, Inc. (MAIA) stock
Close on Nov 12, 2026Market cap $61.43MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $61.43M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.19
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$25.12M
- EPS, diluted
- -$0.49
- Book value per share
- $0.24
- Diluted shares
- 61M
Trading
- Previous close
- $1.03
- Open
- $1.03
- Day's range
- $1.00 – $1.06
- Volume
- 273,938
- Average volume (20 days)
- 257,623
- Beta (5 years)
- 1.08
- 52-week range
- $0.87 – $3.19
- RSI (14 days)
- 37.4
- Volatility (1 year)
- 86.4%
- Relative volume
- 0.58×
- WACC
- 10.4%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MAIA | S&P 500 | Difference | MAIA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.4% | -2.7% | −11.7 pts | ||
| 3 months | -26.8% | -1.7% | −25.1 pts | ||
| Year to date | -34.0% | +11.9% | −45.9 pts | ||
| 1 year | -5.6% | +12.0% | −17.6 pts | ||
| 3 years | -49.2% | +78.2% | −127.4 pts | -20.2% | +21.2% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases MAIA Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
- Update
About MAIA Biotechnology
Pharmaceutical Preparations
MAIA Biotechnology, Inc. is a clinical-stage biotechnology entity engaged in the research, development, and advancement of targeted oncology treatments. The enterprise primarily focuses on investigational therapies targeting telomeres and cancer cell processes to combat complex malignancies. Its therapeutic pipeline includes clinical and technological development centered on THIO (ateganosine), aimed at addressing severe oncological conditions for patients with advanced cancers. The enterprise coordinates research activities alongside collaboration and licensing agreements established with research institutions and industry partners.
Company profile, executives and historyMAIA Biotechnology stock: common questions
What is MAIA Biotechnology's stock price?
MAIA closed at $1.01 on Nov 12, 2026, down 1.94% on the day. Over the past 52 weeks it traded between $0.87 and $3.19.
What is MAIA Biotechnology's market cap?
MAIA Biotechnology was worth $61.43M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MAIA's P/E ratio?
MAIA Biotechnology lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.49), so it has no meaningful P/E ratio.
Does MAIA Biotechnology pay a dividend?
No. MAIA Biotechnology has not paid a cash dividend over the last twelve months.
How has MAIA stock performed over the past year?
Including dividends, MAIA returned -5.6% over the past year, against +12.0% for the S&P 500.
How many MAIA shares are sold short?
2M shares were sold short at the latest FINRA report, 4.74% of the float, or 9.0 days of average trading volume.
Who are MAIA Biotechnology's competitors?
Companies most similar to MAIA Biotechnology by business, industry and size include KZIA, APLM, TNGX, NBP, OTLC.
See a number that looks wrong?